Table 3.
Overall and progression-free survival times according to clinical parameters and NLR, DNLR, LMR, PLR and changes of these parameters after therapy (n=26)
| Parameters | Total (n) | Total (%) | OS
|
PFS
|
||||
|---|---|---|---|---|---|---|---|---|
| Mean | Median | P-value | Mean | Median | P-value | |||
|
| ||||||||
| Age (years) | ||||||||
| <65 | 22 | 84.6 | 20.16 | 14.70 | 0.623 | 11.89 | 5.40 | 0.606 |
| ≥65 | 4 | 15.4 | 15.55 | 8.23 | 10.72 | 8.23 | ||
| Gender | ||||||||
| Female | 14 | 53.8 | 21.99 | 20.97 | 0.611 | 11.52 | 5.03 | 0.727 |
| Male | 12 | 46.2 | 16.08 | 8.23 | 10.65 | 7.20 | ||
| Grade | ||||||||
| II | 9 | 34.6 | 25.10 | 23.13 | 0.285 | 13.56 | 11.33 | 0.290 |
| III | 17 | 65.4 | 15.44 | 7.93 | 9.76 | 5.40 | ||
| Pazopanib line | ||||||||
| 2–3 | 20 | 76.9 | 21.42 | 20.97 | 0.142 | 12.42 | 7.90 | 0.331 |
| 4 | 6 | 23.1 | 11.60 | 5.87 | 7.25 | 4.33 | ||
| Initial response | ||||||||
| Regression/stable | 13 | 50 | 31.35 | 23.13 | 0.001 | 20.09 | 12.03 | 0.000 |
| Progression | 13 | 50 | 8.87 | 5.03 | 4.67 | 4.33 | ||
| NLR | ||||||||
| <4.8 | 15 | 57.6 | 25.66 | 23.13 | 0.022 | 14.26 | 7.2 | 0.365 |
| ≥4.8 | 11 | 42.4 | 11.33 | 5.87 | 7.82 | 5.4 | ||
| DNLR | ||||||||
| <3.1 | 16 | 61.5 | 25.74 | 23.13 | 0.018 | 15.98 | 11.37 | 0.007 |
| ≥3.1 | 10 | 38.5 | 10.52 | 5.03 | 5.50 | 4.47 | ||
| LMR | ||||||||
| <3.6 | 11 | 42.3 | 14.44 | 7.93 | 0.167 | 10.56 | 7.20 | 0.732 |
| ≥3.6 | 15 | 57.7 | 25.62 | 22.23 | 11.18 | 7.90 | ||
| PLR | ||||||||
| <195 | 6 | 23.1 | 23.44 | 22.33 | 0.031 | 13.64 | 7.20 | 0.358 |
| ≥195 | 20 | 76.9 | 11.35 | 4.93 | 7.66 | 4.93 | ||
| D NLR | ||||||||
| Decrease | 10 | 38.5 | 30.82 | 23.13 | 0.021 | 17.85 | 12.03 | 0.005 |
| Increase | 16 | 61.5 | 11.38 | 5.60 | 7.17 | 4.47 | ||
| D DNLR | ||||||||
| Decrease | 12 | 46.2 | 29.73 | 23.13 | 0.010 | 19.81 | 12.03 | 0.001 |
| Increase | 14 | 53.8 | 10.10 | 5.87 | 5.37 | 4.33 | ||
| D LMR | ||||||||
| Decrease | 13 | 50 | 19.23 | 14.70 | 0.881 | 8.53 | 5.03 | 0.204 |
| Increase | 13 | 50 | 17.88 | 19.23 | 13.56 | 8.23 | ||
| D PLR | ||||||||
| Decrease | 11 | 42.3 | 21.14 | 19.23 | 0.557 | 17.14 | 8.23 | 0.063 |
| Increase | 15 | 57.7 | 16.72 | 7.93 | 6.29 | 5.03 | ||
| Overall | 26 | 100 | 19.18 | 14.70 | 11.26 | 7.20 | ||
Note: Bold values indicate statistical significance.
Abbreviations: Δ, change; DNLR, derived neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; PLR, platelet-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; PFS, progression-free survival.